Virax Biolabs Group (VRAX) Competitors $0.91 +0.04 (+4.48%) As of 02:21 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock VRAX vs. SNPX, PHXM, TLPH, CLDI, ADXN, GOVX, GLYC, APRE, XFOR, and CYCNShould you be buying Virax Biolabs Group stock or one of its competitors? The main competitors of Virax Biolabs Group include Synaptogenix (SNPX), PHAXIAM Therapeutics (PHXM), Talphera (TLPH), Calidi Biotherapeutics (CLDI), Addex Therapeutics (ADXN), GeoVax Labs (GOVX), GlycoMimetics (GLYC), Aprea Therapeutics (APRE), X4 Pharmaceuticals (XFOR), and Cyclerion Therapeutics (CYCN). These companies are all part of the "pharmaceutical products" industry. Virax Biolabs Group vs. Its Competitors Synaptogenix PHAXIAM Therapeutics Talphera Calidi Biotherapeutics Addex Therapeutics GeoVax Labs GlycoMimetics Aprea Therapeutics X4 Pharmaceuticals Cyclerion Therapeutics Virax Biolabs Group (NASDAQ:VRAX) and Synaptogenix (NASDAQ:SNPX) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, profitability, valuation, dividends, earnings, analyst recommendations, institutional ownership and risk. Which has preferable earnings and valuation, VRAX or SNPX? Virax Biolabs Group has higher revenue and earnings than Synaptogenix. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVirax Biolabs Group$10K394.51-$6.06MN/AN/ASynaptogenixN/AN/A-$12.77M-$10.08-0.96 Do analysts prefer VRAX or SNPX? Virax Biolabs Group currently has a consensus target price of $3.00, suggesting a potential upside of 230.03%. Given Virax Biolabs Group's stronger consensus rating and higher possible upside, analysts clearly believe Virax Biolabs Group is more favorable than Synaptogenix.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Virax Biolabs Group 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Synaptogenix 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is VRAX or SNPX more profitable? Virax Biolabs Group's return on equity of 0.00% beat Synaptogenix's return on equity.Company Net Margins Return on Equity Return on Assets Virax Biolabs GroupN/A N/A N/A Synaptogenix N/A -115.28%-58.31% Does the media favor VRAX or SNPX? In the previous week, Virax Biolabs Group and Virax Biolabs Group both had 1 articles in the media. Virax Biolabs Group's average media sentiment score of 1.89 beat Synaptogenix's score of 1.87 indicating that Virax Biolabs Group is being referred to more favorably in the media. Company Overall Sentiment Virax Biolabs Group Very Positive Synaptogenix Very Positive Do institutionals & insiders have more ownership in VRAX or SNPX? 8.6% of Virax Biolabs Group shares are owned by institutional investors. Comparatively, 10.3% of Synaptogenix shares are owned by institutional investors. 45.1% of Virax Biolabs Group shares are owned by insiders. Comparatively, 2.7% of Synaptogenix shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Which has more volatility and risk, VRAX or SNPX? Virax Biolabs Group has a beta of 1.65, indicating that its stock price is 65% more volatile than the S&P 500. Comparatively, Synaptogenix has a beta of 1.08, indicating that its stock price is 8% more volatile than the S&P 500. SummaryVirax Biolabs Group beats Synaptogenix on 10 of the 11 factors compared between the two stocks. Get Virax Biolabs Group News Delivered to You Automatically Sign up to receive the latest news and ratings for VRAX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VRAX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VRAX vs. The Competition Export to ExcelMetricVirax Biolabs GroupMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.95M$2.92B$5.56B$9.30BDividend YieldN/A2.43%4.23%4.03%P/E RatioN/A20.3828.6319.67Price / Sales394.51304.58439.23185.66Price / CashN/A43.1536.0257.93Price / Book0.727.738.185.64Net Income-$6.06M-$55.11M$3.23B$257.73M7 Day Performance-1.58%0.65%-0.20%0.21%1 Month Performance4.45%8.17%5.43%8.47%1 Year Performance-28.98%-2.67%26.39%13.93% Virax Biolabs Group Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VRAXVirax Biolabs Group3.082 of 5 stars$0.91+4.5%$3.00+230.0%-23.0%$3.95M$10K0.005Positive NewsSNPXSynaptogenix0.3117 of 5 stars$7.63-10.2%$14.00+83.5%+130.2%$10.61MN/A-0.764Positive NewsPHXMPHAXIAM TherapeuticsN/A$3.10flatN/AN/A$10.58MN/A0.0049TLPHTalphera2.3684 of 5 stars$0.50+8.6%$5.00+894.8%-52.5%$10.31M$27K-1.1219CLDICalidi Biotherapeutics0.566 of 5 stars$0.32+33.6%N/A-67.1%$10.21MN/A0.0038Gap UpHigh Trading VolumeADXNAddex Therapeutics2.5147 of 5 stars$9.52+1.5%$30.00+215.1%+8.5%$10.09M$460K-28.0030Positive NewsGap DownGOVXGeoVax Labs2.2181 of 5 stars$0.63+25.4%$11.10+1,661.9%-75.4%$10.04M$3.95M-0.1710Analyst UpgradeHigh Trading VolumeGLYCGlycoMimetics0.5088 of 5 stars$0.16-6.6%N/A-99.5%$10.00M$10K-0.3450High Trading VolumeAPREAprea Therapeutics2.8943 of 5 stars$1.80+4.0%$15.50+761.1%-58.4%$9.95M$1.50M-0.767Gap UpXFORX4 Pharmaceuticals4.925 of 5 stars$1.69flat$72.33+4,192.8%-93.1%$9.76M$2.56M0.7980Positive NewsGap UpHigh Trading VolumeCYCNCyclerion Therapeutics2.5311 of 5 stars$3.01-2.6%N/A+8.9%$9.66M$2M-2.5930News Coverage Related Companies and Tools Related Companies Synaptogenix Competitors PHAXIAM Therapeutics Competitors Talphera Competitors Calidi Biotherapeutics Competitors Addex Therapeutics Competitors GeoVax Labs Competitors GlycoMimetics Competitors Aprea Therapeutics Competitors X4 Pharmaceuticals Competitors Cyclerion Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VRAX) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersWall Street Hates This Gold IRA Strategy—Here’s WhyWhat if I told you there's a legal way to own real physical gold and silver—and keep your gains tax-free? N...Advantage Gold | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredDrilling With a $3.5B Discovery Partner in Its CornerA small-cap explorer is about to drill for high-grade gold in a region known for multi-million-ounce discoveri...The Tomorrow Investor | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredRevolutionary AI Tech Targets Early Diabetic Blindness Detection FDA Trial UnderwayTiny Stock, Massive Potential— this company’s AI platform is a game changer for healthcare!Interactive Offers | SponsoredThis Social Security Shift Could Boost Benefits by 400%If you currently collect Social Security—or plan to in the future—this may be one of the most important update...InvestorPlace | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Virax Biolabs Group Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Virax Biolabs Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
